Posts Tagged 'ketoacidosis'

Invokana Now Carries an Additional Risk: Circumcision

invokana linked to circumcision riskPatients taking Invokana and other SGLT2 inhibitors to treat and control their Type II diabetes have done so with the risk of a wide variety of adverse side effects for quite some time. The drugs’ links to serious conditions like bone fractures, kidney failure, and a particularly dangerous condition known as ketoacidosis are well established. They can strike anyone – young, old, men, and women.

However, there is another risk ...

continue reading...

Diabetic Ketoacidosis Connection Remains despite SGLT2 Inhibitor Trial Results

A recent Reuters article reports that Eli Lilly & Co. and Boehringer Ingelheim have received positive results for their sodium-glucose cotransporter-2 (SGLT2) inhibitor Jardiance. According to a recent drug trial, empagliflozin (Jardiance) can cut patients’ risk of cardiovascular problems like heart attack and stroke. But Jardiance and other SGLT2 inhibitors still cannot seem to escape the shadow of diabetic ketoacidosis, a potentially fatal blood condition to which the new class of diabetes drugs has ...

continue reading...

New Thoughts on SGLT2 Inhibitor–Induced Diabetic Ketoacidosis

questions remain about sglt2 inhibitorsWhile sodium-glucose cotransporter-2 (SGLT2) inhibitors draw praise for their weight-loss and blood pressure reduction benefits, medical experts continue to puzzle over their more immediate metabolic and immune system effects. Specifically, researchers are worried about their possible link to diabetic ketoacidosis, a potentially fatal condition caused by excess blood acids, or ketones. In an article published by the Journal of Diabetes Investigation, two Japanese researchers provide a possible explanation for how continue reading...

Endocrinologists to Explore Link between SGLT2 Inhibitors and Diabetic Ketoacidosis

endocrinologists exploring sglt2 inhibitor link to ketoacidosisThe American Association of Clinical Endocrinologists (AACE) has begun looking into the possible link between sodium-glucose cotransporter-2 (SGLT2) inhibitors, an emerging class of diabetes drugs, and the severe blood condition known as diabetic ketoacidosis. According to Diabetes.co.uk, the AACE plans to hold a conference on the subject in late October.

SGLT2 inhibitors are a new type of diabetes medication approved by the U.S. Food and Drug Administration (FDA) for ...

continue reading...

Consumer Advocates Speak Out against Off-Label SGLT2 Inhibitor Promotion

public citizen speaking out about off-label marketing In a recent letter to the U.S. Food and Drug Administration (FDA), Public Citizen, a 350,000-member consumer advocacy group, spoke out against the apparent off-label promotion of certain sodium-glucose cotransporter 2 (SGLT2) inhibitors. The group takes issue with direct-to-consumer advertisements for five different drugs: Farxiga (dapagliflozin), Jardiance (empagliflozin), Invokana (canagliflozin), Victoza (liraglutide), and Bydureon (extended-release exenatide). According to Public Citizen, ads in print magazines and online are inappropriately promoting ...

continue reading...

SGLT2 Inhibitors and Ketoacidosis: What Patients Should Know

FDA safety announcement issued over ketoacidosis link to SGLT2 inhibitorsLast month, the U.S. Food and Drug Administration (FDA) issued a safety announcement in which it warned of a possible connection between a new type of diabetes medication, called sodium-glucose cotransporter-2 (SGLT2) inhibitors, and ketoacidosis, a serious blood condition wherein the body produces too many blood acids, or ketones. Since the alert, there have been questions from patients as well as practitioners about the drugs’ link ...

continue reading...
Page 1 of 2 12